Structure Therapeutics Inc. (GPCR)
| Market Cap | 2.83B +82.9% |
| Revenue (ttm) | n/a |
| Net Income | -170.34M |
| EPS | -2.40 |
| Shares Out | 71.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 825,642 |
| Open | 38.00 |
| Previous Close | 38.08 |
| Day's Range | 36.93 - 40.00 |
| 52-Week Range | 15.80 - 94.90 |
| Beta | -1.39 |
| Analysts | Strong Buy |
| Price Target | 105.73 (+165.39%) |
| Earnings Date | May 7, 2026 |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for GPCR stock is "Strong Buy." The 12-month stock price target is $105.73, which is an increase of 165.39% from the latest price.
News
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially com...
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me...
Canaccord starts Structure Therapeutics on oral weight loss pipeline
Canaccord initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $101 price target The stock in premarket trading is up 3% to $46.90. The firm says Structure is…
Structure Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $101 price target
Structure Therapeutics appoints Matthew Lang as COO
Structure Therapeutics (GPCR) announced the appointment of Matthew Lang as COO and general counsel. Lang most recently served as chief legal officer and secretary at Metsera.
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me...
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Structure Therapeutics (GPCR) to $100 from $114 and keeps a Buy rating on the shares. While the company reported “breakthrough” 44-week data…
Structure’s GLP-1 pill could put company on M&A radar, Barron’s says
Structure Therapeutics (GPCR) said its GLP-1 pill helped patients lose over 16% of their weight, on average, in a 10-month drug trial, Bill Alpert of Barron’s writes. Weight loss continued…
Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?
Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.
Structure Therapeutics Transcript: Study result
Aleniglipron showed up to 16.3% weight loss at 44 weeks with no plateauing, and a 'start low, go slow' titration strategy improved tolerability and minimized discontinuations. No serious safety concerns were observed, and phase III will build on these findings.
Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study
Structure Therapeutics (GPCR) announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related...
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral G...
Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Structure Therapeutics (GPCR) to $114 from $90 and keeps a Buy rating on the shares. The firm believes the 44-week ACCESS II…
Structure Therapeutics price target lowered to $113 from $120 at Citizens
Citizens analyst Jonathan Wolleben lowered the firm’s price target on Structure Therapeutics (GPCR) to $113 from $120 and keeps an Outperform rating on the shares. Structure Therapeutics is entering a...
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
Structure Therapeutics emerges as top M&A target for big pharma, Axios says
Structure Therapeutics (GPCR), which his working on next-gen oral obesity medication, has emerged as the next top M&A target for Big Pharma, Axios’ Katherine Davis reports. The new market for…
Structure Therapeutics price target raised to $105 from $65 at JPMorgan
JPMorgan raised the firm’s price target on Structure Therapeutics (GPCR) to $105 from $65 and keeps an Overweight rating on the shares. The firm sees the upcoming data of the…
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s
Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.
Structure Therapeutics price target raised to $140 from $90 at Guggenheim
Guggenheim raised the firm’s price target on Structure Therapeutics (GPCR) to $140 from $90 and keeps a Buy rating on the shares. The firm is updating its model to reflect…
Structure Therapeutics moved to Buy rating at Goldman Sachs
Goldman Sachs moved Structure Therapeutics (GPCR) to Buy rating and $102 price target from Early Stage Biotech. The company’s oral small molecule GLP-1 aleniglipron has shown to be competitive against...
Structure CEO Ray Stevens talks its obesity drug portfolio
Ray Stevens, Structure CEO, joins 'Fast Money' to talk its weigh-loss drug pipeline, potential M&A, and more.
Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
Shares of several names in the obesity-drug space, including Viking Therapeutics (VKTX), Terns Pharmaceuticals (TERN), and Structure Therapeutics (GPCR), are moving higher on Wednesday following comme...
Structure Therapeutics rises 14.1%
Structure Therapeutics (GPCR) is up 14.1%, or $9.79 to $79.15.
Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright
H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics (GPCR) to $90 from $60 and keeps a Buy rating on the shares. The firm says its…